Skip to main content

Our pipeline programs are designed to make a significant impact for patients.

FogPharma’s first-in-class development programs target important, common drivers of cancer that are widely considered to be “undruggable.” Our programs are designed to drastically reduce the burden of disease on patients and their families.

Hit Identification

Discovery

Pre-Clinical Development

Development

β-catenin

FOG-001 (β-catenin/TCF4 Inhibitor)
β-catenin Degrader

ERG

ERG Degrader
ERG/DNA Binding Inhibitor

AR

Non-Androgen Site Degrader

Early Portfolio

Multiple Targets

Helicon-enabled alpha radioligand therapies

Multiple Targets

The future of precision medicine begins now.

View Our Science